Catheter ablation of atrial arrhythmias to prevent ventricular tachycardia in a patient with mobile left ventricular thrombus

Arjun S. Patel, MD, Edmond M. Cronin, MB, BCh, BAO, FHRS, CCDS

From the Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.

Introduction
Atrial fibrillation (AF) is a leading cause of inappropriate shocks in patients with an implantable cardioverter-defibrillator (ICD), but can also trigger episodes of ventricular tachycardia (VT) or ventricular fibrillation (VF), leading to appropriate ICD therapies.1 Although many antiarrhythmic drugs have effects on both atrial and ventricular arrhythmias, catheter ablation is an effective therapy for both AF and VT, especially when refractory to antiarrhythmics. Left ventricular (LV) thrombus is an important contraindication to endocardial VT ablation.2

Case report
A 70-year-old man, with a long history of coronary artery disease, remote coronary artery bypass grafting, asbestosis, paroxysmal AF, and a secondary prevention ICD implanted initially in 1993 for syncope with severe LV dysfunction, presented with recurrent appropriate ICD shocks for VT. These were preceded by days to weeks of symptoms of palpitations, shortness of breath, and reduced exercise tolerance. He had been treated with sotalol and mexiletine, although the dose of the former was limited to 80 mg twice daily owing to chronic kidney disease and sinus bradycardia, for which he had undergone upgrade to a dual-chamber ICD. Despite this, he had received 3 appropriate shocks in the last year. He also had a history of LV thrombus treated with warfarin, which had been stopped 6 months earlier after an echocardiogram demonstrated resolution. However, repeat echocardiography had shown inferior LV akinesis with apical dyskinesis and an ejection fraction of approximately 40%, with reappearance of a mobile, protruding apical LV thrombus, and warfarin was restarted (Figure 1).

He complained of New York Heart Association class IIIa heart failure symptoms, including shortness of breath when showering. In addition to the above medications, the patient was receiving maximum tolerated guideline-directed medical therapy.

Twelve-lead electrocardiogram showed sinus rhythm with inferior Q waves and occasional premature ventricular contractions from the basal anterolateral LV. Interrogation of his dual-chamber ICD showed that VT events occurred solely during episodes of AF (Figure 2A), but intracardiac electrograms confirmed appropriate therapies for VT, and not inappropriate therapies for rapidly conducted AF (Figure 3). This was also suggested on review of records of his prior single-chamber device, which showed that VT had occurred at times when his heart rate had been elevated for the preceding several days. AF burden was 4.2% despite sotalol therapy.

Owing to the presence of mobile, protruding LV thrombus, endocardial catheter ablation was contraindicated; instead, catheter ablation of AF was pursued to eliminate this
trig. Intracardiac echocardiography confirmed the presence of LV thrombus. Although the patient presented in atrial paced rhythm, a single atrial extrastimulus from the high right atrium induced atypical atrial flutter. Via transseptal puncture, activation mapping of the left atrium (LA) using a multi-electrode catheter (PentaRay; Biosense Webster, Diamond Bar, CA) and electroanatomic mapping system (CARTO 3; Biosense Webster) suggested perimital flutter. In sinus rhythm, bipolar voltage mapping revealed extensive LA scar, encompassing the septum and posterior wall, with the inferior and lateral LA and the LA appendage having normal voltage (>0.4 mV). In addition, roof-dependent flutter, and a focal atrial tachycardia from the septal aspect of the mitral annulus, were induced and ablated. The final lesion set included pulmonary vein isolation, an anteroseptal mitral isthmus line through an area of scar, and box isolation of the posterior wall (Supplemental Figure).

At follow-up at over 1 year postablation, with unchanged medical therapy, ICD interrogation revealed no further VT or ICD therapies and an AF burden of <0.1% (Figure 2B). The patient reported freedom from symptoms of palpitation and reduced anxiety regarding ICD shocks, but unchanged exercise tolerance.

**Discussion**

AF is common in patients with ICDs, with episodes lasting more than 24 hours occurring in 7.1% of dual-chamber ICD recipients without a prior history of atrial arrhythmia.
during follow-up of 22 ± 9 months in a recent study, and a prevalence of 20% in a contemporaneous cross-sectional study. AF is also the most common cause of inappropriate ICD shocks, when it is rapidly conducted to the ventricles. Perhaps less well recognized, however, is that the risk of VT/VF and therefore appropriate ICD therapies also rises during episodes of atrial arrhythmia. Early investigations of stored electrograms from single-chamber ICDs suggested that 6%-10% of VT/VF episodes were preceded by AF. An analysis of adjudicated dual-chamber ICD electrograms from 537 patients found that AF preceded VT/VF in 8.6% of VT/VF episodes, within 1 hour half of the time. In addition, continued AF after termination of VT/VF was associated with a much shorter time until the next VT/VF episode vs cases where AF terminated with the ICD shock, suggesting a role for AF in facilitating initiation of ventricular arrhythmia. Another prospective study found that AF was an independent predictor of appropriate (as well as inappropriate) ICD shocks, often preceded by short-long-short sequences. These findings have been reproduced by several other investigators. Effective rhythm control of AF therefore presents a therapeutic opportunity for patients with VT. While many of the antiarrhythmic drugs used for AF will also act to reduce episodes of VT, when refractory, catheter ablation may provide an effective option.

There may be several mechanisms by which AF can trigger VT/VF. Firstly, irregular rhythms such as AF produce long-short sequences, which may induce reentry. This may be particularly important in patients with ICDs, in whom ventricular pacing can result, and is associated with an increased risk of appropriate ICD shocks. Irregularity is associated with QTc prolongation and increased QT dispersion compared to a regular rhythm, suggesting that irregularity itself leads to electrical remodeling, which predisposes to ventricular arrhythmia. The increased risk of ventricular arrhythmia in patients with AF has been found to be enhanced by the presence of QRS and QT prolongation, further suggesting that both abnormal depolarization and repolarization play a role in these events. Other possible mechanisms include hemodynamic impairment, increased sympathetic tone, rate-related ischemia, and tachycardia-induced cardiomyopathy; further study is needed to clarify the role of each.

LV thrombus is generally regarded as a contraindication to endocardial ablation. Successful ablation has been reported in a very limited number of patients with old, laminated thrombus, although not without a risk of stroke. This patient, however, had a relatively new, recurrent, and mobile thrombus that protruded into the LV cavity, which would likely lead to a higher risk of embolism. Alternatively, epicardial-only ablation has been reported in a small number of patients, including cases with LV thrombus. This patient had a history of coronary artery bypass grafting, which makes epicardial access particularly challenging, with a success rate of 60% in 1 study. Therefore, ablation of atrial arrhythmias in this case was a feasible alternative to VT ablation.

Conclusion
AF acts as a trigger of VT/VF in patients with ICDs. In these patients, AF presents a therapeutic opportunity, as illustrated by this case, in which ablation of atrial arrhythmias was associated with control of drug-refractory VT.

Appendix
Supplementary data
Supplementary data associated with this article can be found in the online version at https://doi.org/10.1016/j.hrcr.2021.07.005.

References
1. Stem KM, Euler DE, Mehra R, et al; Jewel AF Worldwide Investigators. Do atrial tachyarrhythmias begat ventricular tachyarrhythmias in defibrillator recipients? J Am Coll Cardiol 2002;40:335-340.

Figure 3 Single-chamber implantable cardioverter-defibrillator (ICD, Protecta XT VR; Medtronic, Minneapolis, MN) electrogram showing ventricular tachycardia treated by an ICD shock followed by a slower, irregular rhythm consistent with atrial fibrillation. Top: right ventricle (RV) tip to ring; middle: RV coil to can; bottom: marker channel.
2. Cronin EM, Bogun FM, Maury P, et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Heart Rhythm 2020;17:e2–e154.

3. Zweibel S, Cronin EM, Schloss EJ, et al. Estimating the incidence of atrial fibrillation in single-chamber implantable cardioverter defibrillator patients. Pacing Clin Electrophysiol 2019;42:132–138.

4. Merchant FM, Desai Y, Addish MA, et al. Implantable cardioverter-defibrillator placement for primary prevention in 2,346 patients: predictors of one-year survival. Tex Heart Inst J 2018;45:221–225.

5. Auricchio A, Schloss EJ, Kurita T, et al. Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: PainFree SST trial primary results. Heart Rhythm 2015;12:926–936.

6. Marchlinski FE, Gottlieb CD, Sarter B, et al. ICD data storage: value in arrhythmia management. Pacing Clin Electrophysiol 1993;16:527–534.

7. Roelke M, Garan H, McGovern BA, Ruskin JN. Analysis of the initiation of spontaneous monomorphic ventricular tachycardia by stored intracardiac electrograms. J Am Coll Cardiol 1994;23:117–122.

8. Grönefeld GC, Maass O, Li YG, Klingenberg T, Hohnloser SH. Association between atrial fibrillation and appropriate implantable cardioverter defibrillator therapy: results from a prospective study. J Cardiovasc Electrophysiol 2000;11:1208–1214.

9. Lemola K, Khan R, Nattel S, et al. Ventricular proarrhythmic effects of atrial fibrillation are modulated by depolarization and repolarization anomalies in patients with left ventricular dysfunction. Pacing Clin Electrophysiol 2009;32:99–105.

10. Cronin EM, Jones P, Seth MC, Varma N. Right ventricular pacing increases risk of appropriate implantable cardioverter-defibrillator shocks asymmetrically: an analysis of the ALTITUDE database. Circ Arrhythm Electrophysiol 2017;10:e004711.

11. Akoum NW, Sanders NA, Wasmund SL, Hamdan MH. Irregular ventricular activation results in QT prolongation and increased QT dispersion: a new insight into the mechanism of AF-induced ventricular arrhythmogenesis. J Cardiovasc Electrophysiol 2011;22:1249–1252.

12. Peichl P, Wichterle D, Cihak R, Aldhoon B, Kautzner J. Catheter ablation of ventricular tachycardia in the presence of an old endocavitory thrombus guided by intracardiac echocardiography. Pacing Clin Electrophysiol 2016;39:581–587.

13. Rao HB, Yu R, Chitnis N, et al. Ventricular tachycardia ablation in the presence of left ventricular thrombus: safety and efficacy. J Cardiovasc Electrophysiol 2016;27:453–459.

14. Berte B, Yamashita S, Sacher F, et al. Epicardial only mapping and ablation of ventricular tachycardia: a case series. Europace 2016;18:267–273.

15. Killu AM, Ebrille E, Asirvatham SJ, et al. Percutaneous epicardial access for mapping and ablation is feasible in patients with prior cardiac surgery, including coronary bypass surgery. Circ Arrhythm Electrophysiol 2015;8:94–101.